BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210510
DTEND;VALUE=DATE:20210512
DTSTAMP:20260515T181353
CREATED:20210205T092218Z
LAST-MODIFIED:20210205T092218Z
UID:28774-1620604800-1620777599@www.pharmajournalist.com
SUMMARY:SMi’s 5th Annual Highly Potent Active Pharmaceutical Ingredients Conference (HPAPi)
DESCRIPTION:Innovations in HPAPI Containment & Facility Design for Successful Manufacturing \nSponsored by: Catalent Pharma Solutions and FPS Food and Pharma Systems \nChaired by: Justin Mason-Home\, Director\, HPAPI Project Services Limited \nSMi is delighted to announce its 5th Annual Highly Potent Active Pharmaceutical Ingredients Virtual Conference on 10th and 11th May 2021. \n \nHighly Potent Active Pharmaceutical Ingredients (HPAPIs) play an increasing central role in the fight against many diseases. There is an increasing need to protect workers who handle HPAPIs along the life cycle of the drug product manufacturing\, from synthesis of the pharmaceutical active ingredient to distribution of the finished medicinal product. This year’s event will focus on 4 key themes: best practices for toxicological assessment\, innovations in containment and facility design\, advances in the use of robotics and automation in manufacturing processes\, and environmental considerations. Key case studies will be highlighted throughout these themes\, revealing the key challenges for current HPAPI manufacture\, and insights into the latest technological and regulatory advances in this increasingly potent environment. \nAttend the conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPi industry. \nKey Speakers for HPAPi include: \n\nEster Lovsin-Barle\, Head of Product Stewardship and Health\, Takeda\nRichard Denk\, Senior Consultant Aseptic Processing & Containment\, SKAN AG\nRaphael Nudelman\, Director of Chemical & Computational Toxicology\, Teva Pharmaceutical\nOlindo Lazzaro\, Director Global EHS\, AbbVie\nFred Ohsiek\, Senior Specialist\, Cleaning Validation\, Novo Nordisk\nFlorian Grundmann\, MSAT Team Lead\, Cleaning Validation\, Roche\nIldiko Ziegler\, QA Manager\, Vanessa Research\nJack Brown\, Senior Research Fellow\, formerly Boehringer Ingelheim\nReinhold Maeck\, Head of Corp EHS Regulatory Intelligence\, Boehringer Ingelheim\n\nDoreen Parrish\, Head of Corporate Audit\, Global EHS\, Takeda \nKey Reasons to Attend HPAPi: \n\nExplore best practices in hazard assessment and occupational toxicology\nunderstand strategic considerations for planning pilot plants and scaling up manufacturing capabilities for high potency compounds\ndiscover potential for automation and robotics in pharmaceutical manufacturing and technologies for protecting operators from hazardous substances\ndiscuss the opportunities for effective CDMO relationships and explore methods for strengthening those partnerships\nDelve into the expanding ADC market within and beyond oncology\nVirtual conference benefits include virtual exhibition booths packed with information\, networking features to chat and share contact details with attendees\n\nView the full agenda: www.highlypotentapi.com/PJwl
URL:https://www.pharmajournalist.com/event/smis-5th-annual-highly-potent-active-pharmaceutical-ingredients-conference-hpapi/
LOCATION:Online Access Only
ORGANIZER;CN="SMi Events":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210510
DTEND;VALUE=DATE:20210512
DTSTAMP:20260515T181353
CREATED:20210305T123955Z
LAST-MODIFIED:20210308T094548Z
UID:29277-1620604800-1620777599@www.pharmajournalist.com
SUMMARY:SMi’s 21st Annual Pain Therapeutics Conference
DESCRIPTION:Sponsored by: MD Biosciences and Transpharmation \nChaired by Michael Scherz\, Founder & CEO\, Metys Pharma and Naheed Mirza\, Early Development Pain & CNS Specialist \nExplore Cutting Edge Drug Discovery Science and Key Clinical-Stage Pain Therapies in the Pipeline \nSMi’s 21st Pain Therapeutics Conference will focus on looking into research within pain therapeutics. In particular\, the long-term (HEAL) initiative will be discussed and its role in advancing research to reduce the risks of opioid use and misuse and improve pain management\, thereby reducing reliance on opioids and the national opioid public health crisis.  Talks will also address the importance of sex\, gender and race in pain research\, including biomarkers\, molecular targets\, clinical and experimental models of pain. \n \nThe conference also address cutting edge drug discovery science\, preclinical development trends\, analysis of key clinical-stage pain therapies\, with a focus on highlighting the importance of biomarker discovery and its contribution to early stage studies on pain. This will be topped off with a panel debate on rethinking pain clinical trials during the COVID-19 pandemic. And further look into treating painful osteoarthritis of the knee with a novel anti NGF\, anti-TNFα bispecific fusion protein as well as therapeutic novelties signifying a paradigm shift in migraine prevention. Additionally\, the conference will explore Botulinum neurotoxin\, Sigma 1 proteins and AP-325 as novel treatment for neuropathic pain as well as the high unmet medical need to develop a novel non-drowsy skeletal muscle relaxant and explore pain genetics in rare diseases as well as the Opioid Crisis and the future of addiction and Pain Therapeutics. \nJoin Europe’s leading Pain Therapeutics Virtual Conference in May 2021 to explore cutting edge drug discovery science and key clinical-stage pain therapies in the pipeline\, bringing together leading pharmaceutical companies and to discuss solutions for the challenges of clinical trial design and conduct.\n#SMiPain \nKey Reasons to Attend the Conference: \n\nDiscover which innovative new therapies are driving clinical development including case studies from Novaramed and Vapogenix\nExamine the best strategies to generate more funding in pain research clinical trials to eliminate the issue of underfunding\nExplore how COVID-19 has changed the experience of clinical trials and presented an opportunity to reform the way we approach data verification\, data analysis and data collection\nUnderstand the role of biomarkers in evaluating target engagement of new drugs and predicting analgesic efficacy\nVirtual Conference Benefits include virtual exhibition booths packed with information\, networking features to chat and share contact details with other attendees\, and virtual meetings and networking socials.\n\nWHO SHOULD ATTEND \nChief Executive Officer\, Chief Scientific Officers\, Chief Medical Officers\, Managing Directors\, CEO\, Head of Department\, Principal Research Scientists\, Clinical lead\, Clinical Operations in the following fields: \n\nPain and Migraine\nInflammation\nChronic Pain\nNeuropathic Pain\nAnalgesic pre-clinical development\nAnaesthesia and Pain Management\nCNS clinical trials\nIon Channel Pharmacology\nPharmacology Intelligence\nTranslational science\nDrug development\nExploratory development\n\nView the full agenda: http://www.pain-therapeutics.co.uk/PJwl
URL:https://www.pharmajournalist.com/event/smis-21st-annual-pain-therapeutics-conference/
LOCATION:Virtual Conference – Online Access Only
ORGANIZER;CN="SMi Group":MAILTO:EVENTS@SMI-ONLINE.CO.UK
END:VEVENT
END:VCALENDAR